OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Trims Stock Holdings in Inozyme Pharma, Inc. (NASDAQ:INZY)

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC reduced its holdings in shares of Inozyme Pharma, Inc. (NASDAQ:INZY) by 11.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 201,232 shares of the company’s stock after selling 25,000 shares during the quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Inozyme Pharma were worth $557,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of INZY. Harvest Investment Services LLC bought a new stake in Inozyme Pharma during the fourth quarter valued at $31,000. Graham Capital Management L.P. bought a new position in shares of Inozyme Pharma during the 4th quarter valued at $33,000. China Universal Asset Management Co. Ltd. purchased a new stake in Inozyme Pharma during the 4th quarter valued at about $38,000. D. E. Shaw & Co. Inc. purchased a new position in shares of Inozyme Pharma in the fourth quarter worth $49,000. Finally, Palumbo Wealth Management LLC grew its stake in shares of Inozyme Pharma by 52.3% in the fourth quarter. Palumbo Wealth Management LLC now owns 23,281 shares of the company’s stock worth $64,000 after purchasing an additional 7,995 shares during the last quarter. 88.30% of the stock is owned by institutional investors.

Inozyme Pharma Stock Performance

NASDAQ:INZY opened at $1.09 on Wednesday. The company has a market cap of $70.37 million, a price-to-earnings ratio of -0.70 and a beta of 1.35. Inozyme Pharma, Inc. has a 1 year low of $0.72 and a 1 year high of $6.24. The stock’s 50 day simple moving average is $1.03 and its two-hundred day simple moving average is $1.93. The company has a debt-to-equity ratio of 0.51, a current ratio of 7.68 and a quick ratio of 7.68.

Analysts Set New Price Targets

Several research firms have weighed in on INZY. HC Wainwright reiterated a “buy” rating and issued a $16.00 price objective on shares of Inozyme Pharma in a report on Thursday, April 10th. Raymond James dropped their price target on shares of Inozyme Pharma from $24.00 to $12.00 and set an “outperform” rating on the stock in a research note on Wednesday, March 12th. Needham & Company LLC reiterated a “buy” rating and set a $15.00 price target on shares of Inozyme Pharma in a report on Tuesday, April 8th. Piper Sandler reduced their price objective on Inozyme Pharma from $30.00 to $23.00 and set an “overweight” rating for the company in a report on Tuesday, March 11th. Finally, Wedbush reiterated an “outperform” rating and set a $7.00 target price (down from $12.00) on shares of Inozyme Pharma in a research note on Monday, March 10th. Eight analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $14.63.

Inozyme Pharma Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.